Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Inclusion Criteria: * Men and women aged 18 to 60 years * One of more daily sc insulin injections of any insulin type or insulin pump use * Body mass index (BMI) = 30 kg/m2 * Pulmonary function tests (PFTs) conducted at Visit 1: * FEV1 ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted * FVC ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted * Diagnosis of type 1 diabetes for at least 12 months * Good venous access for blood draws * Written informed consent provided * No smoking in the previous 6 months (including cigarette, cigars, pipes) and negative urine cotinine testing (\<100 ng/mL) * C-peptide \< 0.3 ng/mL * Hemoglobin A1c (HbA1c) = 10.0% Exclusion Criteria: * Total daily insulin requirement of = 1.4 U/kg body weight * Serum creatinine = 2.0 mg/dL in men and \> 1.8 mg/dL in women * Blood donation of 500 mL within the previous 56 days * Current treatment with pramlintide acetate or exenatide * Unstable diabetes control and evidence of severe complications of diabetes (ie, autonomic neuropathy) * History of chronic obstructive pulmonary disease (COPD) or asthma, or any other clinically important pulmonary disease confirmed by pulmonary function testing or radiologic findings * Upper respiratory tract infection within 8 weeks before screening * History of coronary artery disease, peripheral vascular disease, or congestive heart failure * Allergy to study drug, food, or other study material (eg, peanuts, soy products) * Clinically significant active or chronic illness * History of drug or alcohol abuse * Positive urine drug screen * Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality * Exposure to any other investigational drug or device within 30 days before treatment or within 90 days before treatment for drugs known to modify glucose metabolism (except metformin) * History of malignancy within the 5 years before screening (other than basal cell carcinoma) * History of human immunodeficiency virus (HIV) infection or hepatitis B or C * Women who are pregnant, lactating, or planning to become pregnant during the clinical study period * Women of childbearing potential (defined as premenopausal and not surgically sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for the purposes of this clinical study includes experiencing amenorrhea for 2 or more years or being surgically sterile * Inability, in the opinion of the PI or a designee, to adequately inhale TI Inhalation Powder * Any subject who, in the opinion of the PI or a designee, appears to not be qualified for this study